JP2019513692A5 - - Google Patents

Download PDF

Info

Publication number
JP2019513692A5
JP2019513692A5 JP2018543636A JP2018543636A JP2019513692A5 JP 2019513692 A5 JP2019513692 A5 JP 2019513692A5 JP 2018543636 A JP2018543636 A JP 2018543636A JP 2018543636 A JP2018543636 A JP 2018543636A JP 2019513692 A5 JP2019513692 A5 JP 2019513692A5
Authority
JP
Japan
Prior art keywords
monomer
terminal arm
conjugated
terminal
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018543636A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019513692A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/018343 external-priority patent/WO2017143171A1/en
Publication of JP2019513692A publication Critical patent/JP2019513692A/ja
Publication of JP2019513692A5 publication Critical patent/JP2019513692A5/ja
Priority to JP2022078004A priority Critical patent/JP7516459B2/ja
Priority to JP2024067893A priority patent/JP2024099661A/ja
Pending legal-status Critical Current

Links

JP2018543636A 2016-02-19 2017-02-17 核酸キャリア及び治療上の使用方法 Pending JP2019513692A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022078004A JP7516459B2 (ja) 2016-02-19 2022-05-11 核酸キャリア及び治療上の使用方法
JP2024067893A JP2024099661A (ja) 2016-02-19 2024-04-19 核酸キャリア及び治療上の使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662297200P 2016-02-19 2016-02-19
US62/297,200 2016-02-19
PCT/US2017/018343 WO2017143171A1 (en) 2016-02-19 2017-02-17 Nucleic acid carriers and therapeutic methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022078004A Division JP7516459B2 (ja) 2016-02-19 2022-05-11 核酸キャリア及び治療上の使用方法

Publications (2)

Publication Number Publication Date
JP2019513692A JP2019513692A (ja) 2019-05-30
JP2019513692A5 true JP2019513692A5 (enExample) 2020-03-12

Family

ID=59626355

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018543636A Pending JP2019513692A (ja) 2016-02-19 2017-02-17 核酸キャリア及び治療上の使用方法
JP2022078004A Active JP7516459B2 (ja) 2016-02-19 2022-05-11 核酸キャリア及び治療上の使用方法
JP2024067893A Pending JP2024099661A (ja) 2016-02-19 2024-04-19 核酸キャリア及び治療上の使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022078004A Active JP7516459B2 (ja) 2016-02-19 2022-05-11 核酸キャリア及び治療上の使用方法
JP2024067893A Pending JP2024099661A (ja) 2016-02-19 2024-04-19 核酸キャリア及び治療上の使用方法

Country Status (5)

Country Link
US (2) US12076410B2 (enExample)
EP (1) EP3416691A4 (enExample)
JP (3) JP2019513692A (enExample)
AU (2) AU2017221437A1 (enExample)
WO (1) WO2017143171A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7366541B2 (ja) 2016-02-19 2023-10-23 コード バイオセラピューティクス インコーポレイテッド 核酸キャリア及び治療上の使用方法
WO2017189805A1 (en) 2016-04-27 2017-11-02 Abbvie Inc. Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
AU2018252193B2 (en) 2017-04-14 2024-12-12 Tallac Therapeutics, Inc. Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
AU2018282868B2 (en) 2017-06-16 2023-10-19 Duke University Resonator networks for improved label detection, computation, analyte sensing, and tunable random number generation
US20190269728A1 (en) 2018-03-02 2019-09-05 Sixfold Bioscience Ltd. Compositions for delivery of cargo to cells
BR112020018658A2 (pt) 2018-03-15 2020-12-29 KSQ Therapeutics, Inc. Composições de regulação gênica e métodos para imu-noterapia aprimorada
KR20210102204A (ko) * 2018-10-17 2021-08-19 탈락 테라퓨틱스, 인크. 면역 조절 폴리뉴클레오타이드 컨쥬게이트 및 사용 방법
CN110092826B (zh) * 2019-02-28 2022-04-15 天津大学 CTLA-4类似物CFN13及CFN13-Fc基因和蛋白
WO2020200481A1 (en) * 2019-04-05 2020-10-08 Biontech Rna Pharmaceuticals Gmbh Treatment involving interleukin-2 (il2) and interferon (ifn)
US20230183746A1 (en) 2019-08-30 2023-06-15 Sixfold Bioscience Ltd. Compositions for transfer of cargo to cells
CN116249547B (zh) 2019-11-04 2025-11-14 代码生物疗法公司 脑特异性血管生成抑制剂1(bai1)抗体及其用途
US11920136B2 (en) 2020-02-28 2024-03-05 Tallac Therapeutics, Inc. Transglutaminase-mediated conjugation
EP4143316A2 (en) 2020-04-27 2023-03-08 Sixfold Bioscience Ltd. Compositions containing nucleic acid nanoparticles with modular functionality
WO2025038373A1 (en) * 2023-08-11 2025-02-20 Unm Rainforest Innovations Compositions and methods targeting osteoactivin

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL182237B1 (pl) 1994-03-07 2001-11-30 Dow Chemical Co Sposób przeprowadzania transfekcji komórek i osiagniecia biodostepnosci materialu genetycznego in vitro i ex vivo PL PL
EP1005573B1 (en) * 1997-07-29 2006-05-24 Polyprobe, Inc. Dendritic nucleic acids exhibiting maximal self-assembly
US6287765B1 (en) 1998-05-20 2001-09-11 Molecular Machines, Inc. Methods for detecting and identifying single molecules
AU2002345847B2 (en) 2001-06-21 2008-05-29 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same
EP1530581A4 (en) 2002-06-12 2006-08-30 Datascope Investment Corp POLYMERIC MARKING MOLECULES
MXPA05004588A (es) 2002-10-29 2005-12-14 Coley Pharmaceutical Group Ltd Metodos y productos relacionados con el tratamiento y prevencion de infeccion de virus de hepatitis c.
WO2004053104A2 (en) * 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5’ cpg nucleic acids and methods of use
US20100136614A1 (en) 2005-10-18 2010-06-03 Dan Luo Dendrimer-like modular delivery vector
US9217151B2 (en) 2007-05-16 2015-12-22 California Institute Of Technology Versatile nucleic acid hairpin motif for programming biomolecular self-assembly pathways
WO2008147526A1 (en) 2007-05-23 2008-12-04 The Trustees Of The University Of Pennsylvania Targeted carriers for intracellular drug delivery
MX2010001194A (es) 2007-07-31 2010-07-30 Univ Louisiana State Conjugado de polipeptido-acido nucleico para inmunoprofilaxis o inmunoterapia para desordenes neoplasicos o infecciones.
EP2657342B1 (en) * 2008-08-08 2015-11-18 Genisphere, LLC DNA dendrimers protected against nuclease degradation
US20110206611A1 (en) 2010-02-24 2011-08-25 Genisphere, Llc DNA Dendrimers as Thermal Ablation Devices
US20130018086A1 (en) * 2010-03-16 2013-01-17 Massachusette Institute Of Technology Sirnas targeting exon 10 of pyruvate kinase m2
US20140212503A1 (en) 2011-03-17 2014-07-31 Hyukjin Lee Delivery system
RU2644263C2 (ru) 2012-06-27 2018-02-08 Ф. Хоффманн-Ля Рош Аг Способ отбора и получения селективных и мультиспецифических терапевтических молекул с заданными свойствами, включающих по меньшей мере две различные нацеливающие группировки, и их применения
US9651549B2 (en) 2012-07-13 2017-05-16 Genisphere, Llc Lateral flow assays using DNA dendrimers
HK1214628A1 (zh) 2012-11-05 2016-07-29 Pronai Therapeutics, Inc. 寡核苷酸癌症療法的給藥和施用
CN105073141A (zh) 2013-02-01 2015-11-18 詹尼斯费尔公司 用于将基因递送到细胞的功能化dna树状聚合物
EP2976109B1 (en) * 2013-03-21 2018-07-25 Genisphere, LLC Cellular delivery of dna intercalating agents
MX376384B (es) 2013-11-27 2025-03-07 Zymeworks Bc Inc Construcciones de union a antigenos biespecificas dirigidas a her2.
EP3289084B1 (en) * 2015-04-17 2020-09-16 Genisphere, LLC siRNA INHIBITION OF HUMAN ANTIGEN R EXPRESSION FOR TREATMENT OF CANCER
JP7366541B2 (ja) * 2016-02-19 2023-10-23 コード バイオセラピューティクス インコーポレイテッド 核酸キャリア及び治療上の使用方法

Similar Documents

Publication Publication Date Title
JP2019513692A5 (enExample)
JP2019511474A5 (enExample)
JP7516459B2 (ja) 核酸キャリア及び治療上の使用方法
JP7366541B2 (ja) 核酸キャリア及び治療上の使用方法
Vandghanooni et al. Bispecific therapeutic aptamers for targeted therapy of cancer: a review on cellular perspective
EP2491123B1 (en) Single molecule nucleic acid nanoparticles
EP3559265B1 (en) Method for processing polynucleotides
CN112654346B (zh) 生物分子包覆颗粒和薄膜及其用途
EP3853254A1 (en) Compositions and methods for treating cancer with anti-cd123 immunotherapy
CN111542595A (zh) 经修饰的免疫细胞及其用途
TWI771643B (zh) 一種新穎的cd16陽性自然殺手細胞及一種培養cd16陽性自然殺手細胞的方法
JP2018504896A5 (enExample)
CA3163304A1 (en) Modified immune effector cell and preparation method therefor
Han et al. Regulation of the translation activity of antigen-specific mRNA is responsible for antigen loss and tumor immune escape in a HER2-expressing tumor model
WO2024037477A1 (zh) 双特异性嵌合抗原受体和免疫细胞、制备方法、应用及肿瘤治疗药品
Roque et al. The Interface of Cancer, Their Microenvironment and Nanotechnology.
CN117750946A (zh) 包括唾液酸结合配体的新型颗粒组合物
CN112955554A (zh) 基于适体的car t细胞开关
Yuan et al. CD8+ T Cells in Gastrointestinal Cancer: a Perspective on Targeting MicroRNA
Xu et al. Surface Functionalization of Extracellular Vesicles with Nucleic Acids towards Biomedical Applications
KR102215987B1 (ko) 신규한 rna 간섭 시스템 및 이의 용도
WO2023081767A1 (en) Methods for immunotherapy
WO2025224074A1 (en) Improved engineered immune cell therapies
WO2023152382A1 (en) Artificial microrna construct
KR20250107811A (ko) 조작된 키메라 융합 단백질 조성물 및 그의 사용 방법